Active, not recruitingNCT06485089
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
Studying Other metabolic disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Kansas Medical Center
- Principal Investigator
- Carol J Fabian, MDUniversity of Kansas Medical Center
- Intervention
- tirzepatide(drug)
- Enrollment
- 20 target
- Eligibility
- 40-64 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (2)
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Kansas Medical Center Breast Cancer Prevention Center, Westwood, Kansas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06485089 on ClinicalTrials.govOther trials for Other metabolic disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07536256Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-BeingWaianae Coast Comprehensive Health Center
- RECRUITINGNCT07229170Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss PatientsSan Raffaele Telematic University
- RECRUITINGNANCT05866107App and Body Fat Scale in the Management of Overweight PatientsCapital Medical University
- RECRUITINGNANCT05748990Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in SchizophreniaCentre for Addiction and Mental Health